Cargando…

Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies

Many systemic cytotoxic agents cannot penetrate the blood-brain barrier. Because of this, in approximately 5% of cancer cases, metastatic disease is seen in the leptomeninges. Without treatment, patients with neoplastic meningitis (NM) generally survive for only a matter of weeks. In the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Julie, Schultz, Diana, Grisdale, Kathleen, Groves, Morris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093345/
https://www.ncbi.nlm.nih.gov/pubmed/25031951
_version_ 1782325708280823808
author Walker, Julie
Schultz, Diana
Grisdale, Kathleen
Groves, Morris
author_facet Walker, Julie
Schultz, Diana
Grisdale, Kathleen
Groves, Morris
author_sort Walker, Julie
collection PubMed
description Many systemic cytotoxic agents cannot penetrate the blood-brain barrier. Because of this, in approximately 5% of cancer cases, metastatic disease is seen in the leptomeninges. Without treatment, patients with neoplastic meningitis (NM) generally survive for only a matter of weeks. In the treatment of NM, intraventricular (IVT) topotecan results in progression-free and overall survival outcomes similar to those seen with other IVT chemotherapies, while being particularly well tolerated by most patients. In this article, we present the case studies of five patients with NM, with various primary malignancies, who received treatment with IVT topotecan.
format Online
Article
Text
id pubmed-4093345
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-40933452014-07-16 Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies Walker, Julie Schultz, Diana Grisdale, Kathleen Groves, Morris J Adv Pract Oncol Review Article Many systemic cytotoxic agents cannot penetrate the blood-brain barrier. Because of this, in approximately 5% of cancer cases, metastatic disease is seen in the leptomeninges. Without treatment, patients with neoplastic meningitis (NM) generally survive for only a matter of weeks. In the treatment of NM, intraventricular (IVT) topotecan results in progression-free and overall survival outcomes similar to those seen with other IVT chemotherapies, while being particularly well tolerated by most patients. In this article, we present the case studies of five patients with NM, with various primary malignancies, who received treatment with IVT topotecan. Harborside Press 2012 2012-07-01 /pmc/articles/PMC4093345/ /pubmed/25031951 Text en Copyright © 2012, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Walker, Julie
Schultz, Diana
Grisdale, Kathleen
Groves, Morris
Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies
title Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies
title_full Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies
title_fullStr Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies
title_full_unstemmed Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies
title_short Intraventricular Topotecan for the Treatment of Neoplastic Meningitis: Five Case Studies
title_sort intraventricular topotecan for the treatment of neoplastic meningitis: five case studies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093345/
https://www.ncbi.nlm.nih.gov/pubmed/25031951
work_keys_str_mv AT walkerjulie intraventriculartopotecanforthetreatmentofneoplasticmeningitisfivecasestudies
AT schultzdiana intraventriculartopotecanforthetreatmentofneoplasticmeningitisfivecasestudies
AT grisdalekathleen intraventriculartopotecanforthetreatmentofneoplasticmeningitisfivecasestudies
AT grovesmorris intraventriculartopotecanforthetreatmentofneoplasticmeningitisfivecasestudies